Alterity TherapeuticsATHE
Market Cap: 14.3M
About: Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
Employees: 11
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 9 [Q4 2023] → 9 (+0) [Q1 2024]
0% less ownership
Funds ownership: 0% [Q4 2023] → 0% (-0%) [Q1 2024]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
15% less capital invested
Capital invested by funds: $227K [Q4 2023] → $194K (-$32.9K) [Q1 2024]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
1 Wall Street Analyst provided 1 year price forecasts over the past 6 months
1 analyst rating
Benchmark Robert Wasserman | 148%upside $4 | Speculative Buy Reiterated | 7 Mar 2024 |
Financial journalist opinion
Based on 4 articles about ATHE published over the past 30 days